NORTH BROOKFIELD

Cancer Incidence by Sex, 1993 - 1997 Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | <u>Obs</u> | <u>SIR</u> | | Exp | <u>Obs</u> | <u>SIR</u> | |
|-----------------------|--------------|---------------------|------------------------|-------------------------|-------|------------|------------|--|
| Bladder, Urina | <u>iry</u> | | Melanoma of Skin | | | | | |
| Male | 2.99 | 5 | 167 | Male | 1.79 | 3 | NC* | |
| Female | 1.04 | 2 | NC* | Female | 1.35 | 3 | NC* | |
| Total | 4.03 | 7 | 173 | Total | 3.14 | 6 | 191 | |
| Brain and Oth | er Central N | <u>ervous Syste</u> | <u>em</u> | Multiple Myeloma | | | | |
| Male | 0.99 | 3 | NC* | Male | 0.56 | 0 | NC* | |
| Female | 0.82 | 2 | NC* | Female | 0.48 | 0 | NC* | |
| Total | 1.80 | 5 | 277 | Total | 1.04 | 0 | NC* | |
| Breast | | | Non-Hodgkin's Lymphoma | | | | | |
| Male | 0.19 | 0 | NC* | Male | 2.40 | 3 | NC* | |
| Female | 16.97 | 18 | 106 | Female | 1.97 | 2 | NC* | |
| Total | 17.16 | 18 | 105 | Total | 4.37 | 5 | 114 | |
| Cervix Uteri | | | | Oral Cavity and Pharynx | | | | |
| | | | | Male | 1.93 | 0 | NC* | |
| Female | 1.12 | 2 | NC* | Female | 0.88 | 1 | NC* | |
| | | | | Total | 2.81 | 1 | NC* | |
| Colon / Rectur | <u>n</u> | | | <u>Ovary</u> | | | | |
| Male | 7.52 | 6 | 80 | | | | | |
| Female | 6.71 | 4 | NC* | Female | 2.06 | 1 | NC* | |
| Total | 14.24 | 10 | 70 | | | | | |
| Esophagus | | | | Pancreas | | | | |
| Male | 1.06 | 1 | NC* | Male | 1.12 | 0 | NC* | |
| Female | 0.34 | 1 | NC* | Female | 1.11 | 0 | NC* | |
| Total | 1.41 | 2 | NC* | Total | 2.23 | 0 | NC* | |
| Hodgkin's Disc | <u>ease</u> | | Prostate | | | | | |
| Male | 0.49 | 0 | NC* | Male | 17.74 | 18 | 101 | |
| Female | 0.37 | 0 | NC* | | | | | |
| Total | 0.86 | 0 | NC* | | | | | |
| Kidney and Re | enal Pelvis | | Stomach | | | | | |
| Male | 1.72 | 2 | NC* | Male | 1.29 | 1 | NC* | |
| Female | 0.98 | 0 | NC* | Female | 0.72 | 1 | NC* | |
| Total | 2.70 | 2 | NC* | Total | 2.01 | 2 | NC* | |
| <u>Larynx</u> | | | | <u>Testis</u> | | | | |
| Male | 1.02 | 1 | NC* | Male | 0.71 | 0 | NC* | |

| Female | 0.27 | 0 | NC* | | | | |
|-----------------------------------|-------|----|-----|--------------------------------------|--------|-----|-----|
| Total | 1.30 | 1 | NC* | | | | |
| Leukemia | | | | Thyroid | | | |
| Male | 1.30 | 2 | NC* | Male | 0.36 | 0 | NC* |
| Female | 0.94 | 1 | NC* | Female | 0.91 | 1 | NC* |
| Total | 2.24 | 3 | NC* | Total | 1.27 | 1 | NC* |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corpus and Uterus, NOS | | | |
| Male | 0.59 | 0 | NC* | | | | |
| Female | 0.23 | 0 | NC* | Female | 3.26 | 4 | NC* |
| Total | 0.82 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 9.46 | 13 | 137 | Male | 59.41 | 60 | 101 |
| Female | 6.82 | 6 | 88 | Female | 53.23 | 54 | 101 |
| Total | 16.28 | 19 | 117 | Total | 112.64 | 114 | 101 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when $\mathbf{Obs} < 5$

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \leq 0.001$ level, as well as at the $\mathbf{p} \leq 0.05$ and $\mathbf{p} \leq 0.01$ levels